| |
DoD Resumes Mandatory Anthrax Vaccinations for Select Groups
- NEWS
DoD to Resume Anthrax
Vaccinations
16 Oct 06
The Department of Defense announced today a resumption of the mandatory Anthrax Vaccine Immunization Program
(AVIP) for military personnel, emergency-essential DoD civilians and contractors, based on defined geographic
areas or roles. The policy also allows personnel previously immunized against anthrax, who are no longer
deployed to higher threat areas, to receive follow-up vaccine doses and booster shots on a voluntary basis.
- POLICIES
Approval of Anthrax Vaccine Immunization Program Implementation Plan
08 Feb 07
Implementation of the Anthrax Vaccine Immunization Program (AVIP)
06 Dec 06
Implementation of the AVIP under this memorandum will follow the Assistant
Secretary of Defense for Health Affairs approval of Military Service
implementation plans. Implementation plans should be submitted within 45
days.
Anthrax Vaccine Immunization Program
12 Oct 06
Based on the continued heightened threat to some U.S. personnel of attack with anthrax spores, the DoD will
resume a mandatory Anthrax Vaccine Immunization Program, consistent with FDA guidelines and the best practices
of medicine, for designated military personnel, emergency-essential and comparable DoD civilian employees, and
certain contractor personnel performing essential services. Vaccination is mandatory for those personnel based
on geographic area of assignment aor special mission roles, except as provided under applicable medical and
administrative exemption policies.
Other AVIP Policies
- SERVICE MESSAGES
- PLANNING DOCUMENTS
- DoD AVIP Implementation Instructions
[DOC]
[PDF]
24 Nov 08
Includes AVIP Registry Agreement
- USAF Plan for Implementing the Anthrax Vaccine Implementation Program (AVIP)
[PDF]
18 Jan 07
Includes AVIP Registry Agreement
- SUPPLY AND LOGISTICS
- QUESTIONS & ANSWERS
- EDUCATIONAL PRODUCTS
- FOOD AND DRUG ADMINISTRATION (FDA)
On 15 December 2005, The Food and Drug Administration (FDA) released a Final Order with respect to anthrax
vaccine adsorbed (AVA), to be published in the Federal Register on 19 December 2005.
After review of the comments and finding no additional scientific evidence to alter the proposed
categorization, FDA accepts the previous Panel’s recommendation and adopts Category I as the final category for
AVA and determines AVA to be safe and effective and not misbranded.
View the FDA Final Order
|
